Tonix Pharmaceuticals Holding Corp. 10-K

ITEM 5 – MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES Market Information Our common stock is listed on The NASDAQ Capital Market under the symbol “TNXP”. Holders On March 17, 2025, the closing sale price of our common stock, as reported by The NASDAQ Stock Market, was $16.28 per share. On March 17, 2025, there were approximately 220 holders of record of our common stock. Because many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders. Dividend Policy We have never paid any cash dividends on our capital stock and do not anticipate paying any cash dividends on our common stock in the foreseeable future. We intend to retain future earnings to fund ongoing operations and future capital requirements of our business. Any future determination to pay cash dividends will be at the discretion of the Board and will be dependent upon our financial condition, results of operations, capital requirements and such other factors as the Board deems relevant. Recent Sales of Unregistered Securities None. Repurchases of Equity Securities by the Issuer and Affiliated Purchasers In September 2024, the Board of Directors approved a share repurchase program pursuant to which we may repurchase up to $10.0 million in value of our outstanding common stock from time to time on the open market and in privately negotiated transactions subject to market conditions, share price and other factors. No repurchases occurred during the quarter ended December 31, 2024. Subsequent to December 31, 2024, we repurchased 250,000 of our shares of common stock outstanding under the share repurchase program at prices ranging from $9.98 to $14.33 per share for a gross aggregate cost of approximately $3.0 million. ITEM 6 – [RESERVED] 100